Agree Realty (ADC) is highlighted as a highly attractive Real Estate Investment Trust (REIT) for dividend investors, especially during periods of market instability. The author, Luuk Wierenga, emphasizes ADC's strong dividend strategy and suggests it offers sustainable income potential that long-term investors should consider. Despite having a higher risk tolerance, Wierenga is contemplating building a position in ADC using a unique dividend reinvestment approach. This insight is part of a broader strategy to hold top-tier REITs that provide reliable dividend income and opportunities to buy more shares during market downturns.
Agree Realty (ADC) is noted for its dividend strategy in turbulent markets. For readers following the Real Estate sector, here is Pluang's market snapshot as of Oct 11, 2026 20:21 WIB: Of 34 priced Real Estate-sector US stocks tradable on Pluang, 25 rose and 9 fell today. Notable movers include Opendoor Technologies Inc at USD 2.22 with a 1-day change of -3.06% and 100% buy order activity, Vivmark Residential Common Shares at USD 61.16 with a 1.97% increase, and Digital Realty Trust, Inc. at USD 178.76 with a 1.53% rise and a typical hold time of 93 days.
Sandisk has emerged as a debt-free company with high free cash flow, benefiting significantly from increased AI-driven data center demand following its separation from Western Digital. Its multi-year New Business Model (NBM) contracts secure NAND pri...
XRP price remained stable around $1.39 after researchers disclosed a critical vulnerability in the XRP Ledger that could have created unauthorized tokens. Developers released an emergency fix before the public disclosure, and investigations found no ...
The CKB cryptocurrency token surged 17.65% in just five minutes on Sunday, pushing its 24-hour gain to nearly 30%. The token's price fluctuated between $0.001387 and $0.001747 during the day, with a trading volume exceeding $4.4 million, highlighting...
FREELANDER has completed a global validation program for its FREELANDER 8 model, involving over 1,000 test vehicles across 50+ road types worldwide. The tests covered extreme conditions including deserts, rocky terrain, and heavy rain, ensuring durab...
Helus Pharma is considered a buy as it prepares for the topline results of its Phase 3 trial for HLP003, targeting adjunctive major depressive disorder, expected in the fourth quarter of 2026. The drug uses a unique intermittent dosing model and show...
